Evidence map›Paper›PMID 40177573›Full record

ArticleActa pharmaceutica Sinica. B2025

Protection efficacy of mRNA-based SARS-CoV-2 variant vaccine in non-human primates.

Dongrong Yi, Yongxin Zhang, Jing Wang, Qian Liu, Ling Ma, Quanjie Li, Saisai Guo, Ruifang Zheng, Xiaoyu Li, Xingong Li and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Construction of a localized immune nicheActa pharmaceutica Sinica. B · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dongrong YiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing 100050, China.
Yongxin ZhangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing 100050, China.
Jing WangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing 100050, China.
Qian LiuInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100005, China.
Ling MaInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing 100050, China.
Quanjie LiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing 100050, China.
Saisai GuoInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing 100050, China.
Ruifang ZhengXinjiang Key Laboratory of Uygur Medical Research, Xinjiang Institute of Materia Medica, Urumqi 830004, China.
Xiaoyu LiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing 100050, China.
Xingong LiRinuaGene Biotechnology Co., Ltd., Suzhou 215127, China.
Yijie DongRinuaGene Biotechnology Co., Ltd., Suzhou 215127, China.
Shuaiyao LuInstitute of Medical Biology, Chinese Academy of Medical Sciences, Kunming 650118, China.
Weiguo ZhangRinuaGene Biotechnology Co., Ltd., Suzhou 215127, China.
Xiaozhong PengInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100005, China.
Shan CenInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing 100050, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that evade immunity elicited by vaccination has posed a global challenge to the control of the coronavirus disease 2019 (COVID-19) pandemic. Therefore, developing countermeasures that broadly protect against SARS-CoV-2 and related sarbecoviruses is essential. Herein, we have developed a lipid nanoparticle (LNP)-encapsulated mRNA (mRNA-LNP) encoding the full-length Spike (S) glycoprotein of SARS-CoV-2 (termed RG001), which confers complete protection in a non-human primate model. Intramuscular immunization of two doses of RG001 in Rhesus monkey elicited robust neutralizing antibodies and cellular response against SARS-CoV-2 variants, resulting in significantly protected SARS-CoV-2-infected animals from acute lung lesions and complete inhibition of viral replication in all animals immunized with low or high doses of RG001. More importantly, the third dose of RG001 vaccination elicited effective neutralizing antibodies against current epidemic XBB and JN.1 strains and similar cellular response against SARS-CoV-2 Omicron variants (BA.1, XBB.1.16, and JN.1) were observed in immunized mice. All these results together strongly support the great potential of RG001 in preventing the infection of SARS-CoV-2 variants of concern (VOCs).

Indexed as

Cellular immunityCirculating Omicron sublineagesHumoral immunitymRNA-LNPNon-human primateSARS-CoV-2Spike glycoproteinVaccine

Identifiers

PMID40177573
PMCPMC11959875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.